Reply to Tillotson, Outterson et al, and Burgess et al.

David N. Gilbert; Robert J. Guidos; Helen W. Boucher; George H. Talbot; Brad Spellberg; John E. Edwards; W. Michael Scheld; John S. Bradley; John G. Bartlett

doi:10.1086/655958

Reply to Tillotson, Outterson et al, and Burgess et al.

David N. Gilbert, Robert J. Guidos, Helen W. Boucher, George H. Talbot, Brad Spellberg, John E. Edwards, W. Michael Scheld, John S. Bradley, John G. Bartlett

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	754-755
Number of pages	2
Journal	Clinical Infectious Diseases
Volume	51
Issue number	6
DOIs	https://doi.org/10.1086/655958
State	Published - Sep 15 2010
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/655958

Cite this

@article{57f6800c7c37465f841086bf389b0224,

title = "Reply to Tillotson, Outterson et al, and Burgess et al.",

author = "Gilbert, {David N.} and Guidos, {Robert J.} and Boucher, {Helen W.} and Talbot, {George H.} and Brad Spellberg and Edwards, {John E.} and {Michael Scheld}, W. and Bradley, {John S.} and Bartlett, {John G.}",

note = "Funding Information: as an advisor and/or consultant to Achaogen, Pacific Bioscience, Pfizer, Schering-Plough (Merck), and Advanced Life Sciences. H.W.B. has served as an advisor and/or consultant to Basilea, Cerexa, Cubist, Durata, Johnson & Johnson, Merck, Meth-ylgene, Nabriva, Optimer, Rib-X, Targanta/TMC, Astellas/Theravance, and Pfizer/Wyeth. G.H.T. provides or has recently provided, through Talbot Advisors LLC, consultative services to Actelion, Advanced Life Sciences, Avera, Bausch & Lomb, Calixa, Cempra, Cerexa, Cubist, Durata, Ipsat, Middlebrook, MMM, Nabriva, PTC, Rib-X, Shire, Targanta, Tetraphase, Theravance, ViroPharma, and Wyeth and owns shares in Cerexa, Calixa, and Mpex. B.S. has received grant support from Gilead, Astellas, and Novartis and has served as a consultant for Merck, Pfizer, Arpida, Theravance, Advanced Life Sciences, Basilea, The Medicines Company, Achaogen, Novartis, Cerexa, Wyeth, Trius, Meiji, Zimek Technologies, Eisai, and Anacor and owns shares in Neutropenia Immunotherapy Solutions and NovaDigm Therapeutics. J.E.E. serves on the scientific advisory board of Cerexa; has participated in educational programs regarding fungal infections funded by Pfizer, Merck, and As-tellas; has received research laboratory support from Pfizer, Merck, Enzon, Squibb, and Gilead; has participated in the Bristol-Myers Squibb Freedom to Discovery research program; and is a cofounder of and holds shares in NovaDigm Therapeutics. W.M.S. receives research support from Pfizer. J.S.B.{\textquoteright}s employer, the University of California–San Diego, has received research grants from Cubist, Johnson & Johnson, and Trius and holds consultant contracts with Bayer Pharmaceuticals, Cerexa, Johnson & Johnson, Nabriva, Trius, and Pfizer Pharmaceuticals. R.J.G.: no conflicts.",

year = "2010",

month = sep,

day = "15",

doi = "10.1086/655958",

language = "English (US)",

volume = "51",

pages = "754--755",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Reply to Tillotson, Outterson et al, and Burgess et al.

AU - Gilbert, David N.

AU - Guidos, Robert J.

AU - Boucher, Helen W.

AU - Talbot, George H.

AU - Spellberg, Brad

AU - Edwards, John E.

AU - Michael Scheld, W.

AU - Bradley, John S.

AU - Bartlett, John G.

N1 - Funding Information: as an advisor and/or consultant to Achaogen, Pacific Bioscience, Pfizer, Schering-Plough (Merck), and Advanced Life Sciences. H.W.B. has served as an advisor and/or consultant to Basilea, Cerexa, Cubist, Durata, Johnson & Johnson, Merck, Meth-ylgene, Nabriva, Optimer, Rib-X, Targanta/TMC, Astellas/Theravance, and Pfizer/Wyeth. G.H.T. provides or has recently provided, through Talbot Advisors LLC, consultative services to Actelion, Advanced Life Sciences, Avera, Bausch & Lomb, Calixa, Cempra, Cerexa, Cubist, Durata, Ipsat, Middlebrook, MMM, Nabriva, PTC, Rib-X, Shire, Targanta, Tetraphase, Theravance, ViroPharma, and Wyeth and owns shares in Cerexa, Calixa, and Mpex. B.S. has received grant support from Gilead, Astellas, and Novartis and has served as a consultant for Merck, Pfizer, Arpida, Theravance, Advanced Life Sciences, Basilea, The Medicines Company, Achaogen, Novartis, Cerexa, Wyeth, Trius, Meiji, Zimek Technologies, Eisai, and Anacor and owns shares in Neutropenia Immunotherapy Solutions and NovaDigm Therapeutics. J.E.E. serves on the scientific advisory board of Cerexa; has participated in educational programs regarding fungal infections funded by Pfizer, Merck, and As-tellas; has received research laboratory support from Pfizer, Merck, Enzon, Squibb, and Gilead; has participated in the Bristol-Myers Squibb Freedom to Discovery research program; and is a cofounder of and holds shares in NovaDigm Therapeutics. W.M.S. receives research support from Pfizer. J.S.B.’s employer, the University of California–San Diego, has received research grants from Cubist, Johnson & Johnson, and Trius and holds consultant contracts with Bayer Pharmaceuticals, Cerexa, Johnson & Johnson, Nabriva, Trius, and Pfizer Pharmaceuticals. R.J.G.: no conflicts.

PY - 2010/9/15

Y1 - 2010/9/15

UR - http://www.scopus.com/inward/record.url?scp=77955952771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955952771&partnerID=8YFLogxK

U2 - 10.1086/655958

DO - 10.1086/655958

M3 - Letter

AN - SCOPUS:77955952771

SN - 1058-4838

VL - 51

SP - 754

EP - 755

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Reply to Tillotson, Outterson et al, and Burgess et al.

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this